| Year |
Citation |
Score |
| 2024 |
Glorieux FH, Langdahl B, Chapurlat R, De Beur SJ, Sutton VR, Poole KES, Dahir KM, Orwoll ES, Willie BM, Mikolajewicz N, Zimmermann E, Hosseinitabatabaei S, Ominsky MS, Saville C, Clancy J, et al. Setrusumab for the Treatment of Osteogenesis Imperfecta: 12-Month Results from the Phase 2b Asteroid Study. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 39012717 DOI: 10.1093/jbmr/zjae112 |
0.502 |
|
| 2023 |
Florio M, Kostenuik PJ, Stolina M, Asuncion FJ, Grisanti M, Ke HZ, Ominsky MS. Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured BoneAn Experimental Study in Nonhuman Primates. The Journal of Bone and Joint Surgery. American Volume. PMID 37159527 DOI: 10.2106/JBJS.22.01092 |
0.61 |
|
| 2021 |
Cardinal M, Chretien A, Roels T, Lafont S, Ominsky MS, Devogelaer JP, Manicourt DH, Behets C. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse. Frontiers in Genetics. 12: 705505. PMID 34447412 DOI: 10.3389/fgene.2021.705505 |
0.521 |
|
| 2021 |
Arlt H, Besschetnova T, Ominsky MS, Fredericks DC, Lanske B. Effects of systemically administered abaloparatide, an osteoanabolic PTHrP analog, as an adjuvant therapy for spinal fusion in rats. Jor Spine. 4: e1132. PMID 33778406 DOI: 10.1002/jsp2.1132 |
0.5 |
|
| 2021 |
Dempster DW, Zhou H, Rao SD, Recknor C, Miller PD, Leder BZ, Annett M, Ominsky MS, Mitlak BH. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women with Osteoporosis. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 33434314 DOI: 10.1002/jbmr.4243 |
0.654 |
|
| 2020 |
Arlt H, Mullarkey T, Hu D, Baron R, Ominsky MS, Mitlak B, Lanske B, Besschetnova T. Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice. Bone Reports. 13: 100291. PMID 32637467 DOI: 10.1016/J.Bonr.2020.100291 |
0.632 |
|
| 2020 |
Cardinal M, Dessain A, Roels T, Lafont S, Ominsky MS, Devogelaer JP, Chappard D, Mabilleau G, Ammann P, Nyssen-Behets C, Manicourt DH. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice. Calcified Tissue International. PMID 32025752 DOI: 10.1007/s00223-019-00655-5 |
0.661 |
|
| 2019 |
Besschetnova T, Brooks DJ, Hu D, Nagano K, Nustad J, Ominsky M, Mitlak B, Hattersley G, Bouxsein ML, Baron R, Lanske B. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis. Bone. PMID 31051317 DOI: 10.1016/J.Bone.2019.04.025 |
0.645 |
|
| 2019 |
Cardinal M, Tys J, Roels T, Lafont S, Ominsky MS, Devogelaer JP, Chappard D, Mabilleau G, Ammann P, Nyssen-Behets C, Manicourt DH. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta. Bone. 124: 137-147. PMID 31051315 DOI: 10.1016/j.bone.2019.04.011 |
0.688 |
|
| 2019 |
Lanske B, Chandler H, Pierce A, Brown J, Ominsky M, Kostenuik P, Hattersley G. Abaloparatide, a PTH Receptor Agonist with Homology to PTHrP, Enhances Callus Bridging and Biomechanical Properties in Rats with Femoral Fracture. Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society. PMID 30790359 DOI: 10.1002/jor.24254 |
0.488 |
|
| 2018 |
Chandler H, Lanske B, Varela A, Guillot M, Boyer M, Brown J, Pierce A, Ominsky M, Mitlak B, Baron R, Kostenuik P, Hattersley G. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone. PMID 30343166 DOI: 10.1016/J.Bone.2018.10.012 |
0.657 |
|
| 2018 |
Taylor S, Hu R, Pacheco E, Locher K, Pyrah I, Ominsky MS, Boyce RW. Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats. Bone Reports. 8: 95-103. PMID 29955627 DOI: 10.1016/j.bonr.2018.03.002 |
0.602 |
|
| 2018 |
Boyce RW, Brown D, Felx M, Mellal N, Locher K, Pyrah I, Ominsky MS, Taylor S. Decreased osteoprogenitor proliferation precedes attenuation of cancellous bone formation in ovariectomized rats treated with sclerostin antibody. Bone Reports. 8: 90-94. PMID 29955626 DOI: 10.1016/j.bonr.2018.03.001 |
0.577 |
|
| 2018 |
Zhao W, Li X, Peng Y, Qin Y, Pan J, Li J, Xu A, Ominsky MS, Cardozo C, Feng JQ, Ke HZ, Bauman WA, Qin W. Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury. Calcified Tissue International. PMID 29931461 DOI: 10.1007/S00223-018-0439-8 |
0.589 |
|
| 2018 |
Liu M, Kurimoto P, Zhang J, Niu QT, Stolina M, Dechow PC, Feng JQ, Hesterman J, Silva MD, Ominsky MS, Richards WG, Ke H, Kostenuik PJ. Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss. Journal of Dental Research. 22034518766874. PMID 29617179 DOI: 10.1177/0022034518766874 |
0.654 |
|
| 2017 |
Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of the Usa. PMID 29260289 DOI: 10.1007/S00198-017-4323-6 |
0.659 |
|
| 2017 |
Li X, Ominsky MS, Villasenor KS, Niu QT, Asuncion FJ, Xia X, Grisanti M, Wronski TJ, Simonet WS, Ke HZ. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis. Endocrinology. PMID 29069393 DOI: 10.1210/En.2017-00794 |
0.689 |
|
| 2017 |
Tsourdi E, Lademann F, Ominsky MS, Rijntjes E, Köhrle J, Misof BM, Roschger P, Klaushofer K, Hofbauer LC, Rauner M. Sclerostin blockade and zoledronic acid improve bone mass and strength in male mice with exogenous hyperthyroidism. Endocrinology. PMID 28973221 DOI: 10.1210/en.2017-00247 |
0.663 |
|
| 2017 |
Li X, Yu L, Asuncion F, Grisanti M, Alexander S, Hensley K, Han CY, Niu QT, Dwyer D, Villasenor K, Stolina M, Dean C, Ominsky MS, Ke HZ, Tomlinson JE, et al. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism. Bone. PMID 28867373 DOI: 10.1016/J.Bone.2017.08.026 |
0.567 |
|
| 2017 |
Shah SA, Kormpakis I, Havlioglu N, Ominsky MS, Galatz LM, Thomopoulos S. Sclerostin Antibody Treatment Enhances Rotator Cuff Tendon-to-Bone Healing in an Animal Model. The Journal of Bone and Joint Surgery. American Volume. 99: 855-864. PMID 28509826 DOI: 10.2106/Jbjs.16.01019 |
0.626 |
|
| 2017 |
Boyce RW, Niu QT, Ominsky MS. Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys. Bone. PMID 28428078 DOI: 10.1016/j.bone.2017.04.005 |
0.691 |
|
| 2017 |
Jolette J, Attalla B, Varela A, Long GG, Mellal N, Trimm S, Smith SY, Ominsky MS, Hattersley G. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34). Regulatory Toxicology and Pharmacology : Rtp. PMID 28389324 DOI: 10.1016/j.yrtph.2017.04.001 |
0.486 |
|
| 2017 |
Matheny JB, Torres AM, Ominsky MS, Hernandez CJ. Romosozumab Treatment Converts Trabecular Rods into Trabecular Plates in Male Cynomolgus Monkeys. Calcified Tissue International. PMID 28246926 DOI: 10.1007/s00223-017-0258-3 |
0.688 |
|
| 2016 |
Ominsky MS, Boyd SK, Varela A, Jolette J, Felx M, Doyle N, Mellal N, Smith SY, Locher K, Buntich S, Pyrah I, Boyce RW. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 27865001 DOI: 10.1002/jbmr.3036 |
0.671 |
|
| 2016 |
Kim SW, Lu Y, Williams EA, Lai F, Lee JY, Enishi T, Balani DH, Ominsky MS, Ke HZ, Kronenberg HM, Wein MN. Sclerostin Antibody Administration Converts Bone Lining Cells into Active Osteoblasts. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 27862326 DOI: 10.1002/Jbmr.3038 |
0.555 |
|
| 2016 |
Ominsky MS, Boyce RW, Li X, Ke HZ. Effects of sclerostin antibodies in animal models of osteoporosis. Bone. PMID 27789417 DOI: 10.1016/J.Bone.2016.10.019 |
0.718 |
|
| 2016 |
Chouinard L, Felx M, Mellal N, Varela A, Mann P, Jolette J, Samadfam R, Smith SY, Locher K, Buntich S, Ominsky MS, Pyrah I, Boyce RW. Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regulatory Toxicology and Pharmacology : Rtp. PMID 27569204 DOI: 10.1016/j.yrtph.2016.08.010 |
0.387 |
|
| 2016 |
Li X, Stanislaus S, Asuncion F, Niu QT, Chinookoswong N, Villasenor K, Wang J, Wong P, Boyce R, Dwyer D, Han CY, Chen MM, Liu B, Stolina M, Ke HZ, ... Ominsky MS, et al. FGF21 Is not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 27505721 DOI: 10.1002/Jbmr.2936 |
0.573 |
|
| 2016 |
Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B, Salimi-Moosavi H, Asuncion FJ, Li C, Sun B, Tan HL, Zhang L, Han CY, Case R, Duguay AN, ... ... Ominsky MS, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nature Communications. 7: 11505. PMID 27230681 DOI: 10.1038/Ncomms11505 |
0.672 |
|
| 2016 |
Lee DC, Varela A, Kostenuik PJ, Ominsky MS, Keaveny TM. Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus Monkeys. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 27149403 DOI: 10.1002/jbmr.2830 |
0.486 |
|
| 2016 |
Bonnet N, Gerbaix M, Ominsky M, Ammann P, Kostenuik PJ, Ferrari SL. Influence of Fatigue Loading and Bone Turnover on Bone Strength and Pattern of Experimental Fractures of the Tibia in Mice. Calcified Tissue International. PMID 26945756 DOI: 10.1007/s00223-016-0124-8 |
0.581 |
|
| 2015 |
Toumi H, Benaitreau D, Pallu S, Mazor M, Hambli R, Ominsky M, Lespessailles E. Effects of anti-sclerostin antibody and running on bone remodeling and strength. Bone Reports. 2: 52-58. PMID 28377954 DOI: 10.1016/j.bonr.2015.03.002 |
0.498 |
|
| 2015 |
Taylor S, Ominsky MS, Hu R, Pacheco E, He YD, Brown DL, Aguirre JI, Wronski TJ, Buntich S, Afshari CA, Pyrah I, Nioi P, Boyce RW. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone. PMID 26721737 DOI: 10.1016/j.bone.2015.12.013 |
0.506 |
|
| 2015 |
Grafe I, Alexander S, Yang T, Lietman C, Homan EP, Munivez E, Chen Y, Jiang MM, Bertin T, Dawson B, Asuncion F, Ke HZ, Ominsky MS, Lee B. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 26716893 DOI: 10.1002/Jbmr.2776 |
0.707 |
|
| 2015 |
Tinsley BA, Dukas A, Pensak MJ, Adams DJ, Tang AH, Ominsky MS, Ke HZ, Lieberman JR. Systemic Administration of Sclerostin Antibody Enhances Bone Morphogenetic Protein-Induced Femoral Defect Repair in a Rat Model. The Journal of Bone and Joint Surgery. American Volume. 97: 1852-9. PMID 26582615 DOI: 10.2106/JBJS.O.00171 |
0.557 |
|
| 2015 |
Achiou Z, Toumi H, Touvier J, Boudenot A, Uzbekov R, Ominsky MS, Pallu S, Lespessailles E. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia. Bone. 81: 691-701. PMID 26409255 DOI: 10.1016/j.bone.2015.09.010 |
0.651 |
|
| 2015 |
Ominsky MS, Brown DL, Van G, Cordover D, Pacheco E, Frazier E, Cherepow L, Higgins-Garn M, Aguirre JI, Wronski TJ, Stolina M, Zhou L, Pyrah I, Boyce RW. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone. 81: 380-391. PMID 26261096 DOI: 10.1016/J.Bone.2015.08.007 |
0.596 |
|
| 2015 |
Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW. Journal of Bone and Mineral Research: Volume 30, Issue 5, May 2015, Frontmatter page ii. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 30: 1347. PMID 25959690 DOI: 10.1002/jbmr.2543 |
0.491 |
|
| 2015 |
Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW. Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 30: 1280-9. PMID 25684625 DOI: 10.1002/Jbmr.2480 |
0.688 |
|
| 2015 |
Nioi P, Taylor S, Hu R, Pacheco E, He YD, Hamadeh H, Paszty C, Pyrah I, Ominsky MS, Boyce RW. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 30: 1457-67. PMID 25678055 DOI: 10.1002/jbmr.2482 |
0.461 |
|
| 2015 |
Sinder BP, Salemi JD, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone. 71: 115-23. PMID 25445450 DOI: 10.1016/J.Bone.2014.10.012 |
0.721 |
|
| 2015 |
Kostenuik PJ, Smith SY, Samadfam R, Jolette J, Zhou L, Ominsky MS. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 30: 657-69. PMID 25369992 DOI: 10.1002/Jbmr.2401 |
0.663 |
|
| 2015 |
Lloyd WR, Sinder BP, Salemi J, Ominsky MS, Marini JC, Caird MS, Morris MD, Kozloff KM. Tissue level material composition and mechanical properties in Brtl/+ mouse model of Osteogenesis Imperfecta after sclerostin antibody treatment Progress in Biomedical Optics and Imaging - Proceedings of Spie. 9303. DOI: 10.1117/12.2080261 |
0.715 |
|
| 2015 |
Ominsky MS, Brown DL, Van G, Cordover D, Pacheco E, Frazier E, Cherepow L, Higgins-Garn M, Aguirre JI, Wronski TJ, Stolina M, Zhou L, Pyrah I, Boyce RW. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats Bone. 81: 380-391. DOI: 10.1016/j.bone.2015.08.007 |
0.512 |
|
| 2014 |
Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology. 155: 4785-97. PMID 25259718 DOI: 10.1210/En.2013-1905 |
0.654 |
|
| 2014 |
Stolina M, Dwyer D, Niu QT, Villasenor KS, Kurimoto P, Grisanti M, Han CY, Liu M, Li X, Ominsky MS, Ke HZ, Kostenuik PJ. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone. 67: 305-13. PMID 25093263 DOI: 10.1016/J.Bone.2014.07.031 |
0.614 |
|
| 2014 |
Ominsky MS, Niu QT, Li C, Li X, Ke HZ. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 29: 1424-30. PMID 24967455 DOI: 10.1002/Jbmr.2152 |
0.675 |
|
| 2014 |
Sinder BP, White LE, Salemi JD, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of the Usa. 25: 2097-107. PMID 24803333 DOI: 10.1007/S00198-014-2737-Y |
0.595 |
|
| 2014 |
Suen PK, He YX, Chow DH, Huang L, Li C, Ke HZ, Ominsky MS, Qin L. Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats. Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society. 32: 997-1005. PMID 24782158 DOI: 10.1002/Jor.22636 |
0.668 |
|
| 2014 |
Boyce RW, Varela A, Chouinard L, Bussiere JL, Chellman GJ, Ominsky MS, Pyrah IT. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period. Bone. 64: 314-25. PMID 24727159 DOI: 10.1016/j.bone.2014.04.002 |
0.584 |
|
| 2014 |
Alaee F, Virk MS, Tang H, Sugiyama O, Adams DJ, Stolina M, Dwyer D, Ominsky MS, Ke HZ, Lieberman JR. Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model. Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society. 32: 197-203. PMID 24600701 DOI: 10.1002/jor.22498 |
0.647 |
|
| 2014 |
Ross RD, Edwards LH, Acerbo AS, Ominsky MS, Virdi AS, Sena K, Miller LM, Sumner DR. Bone matrix quality after sclerostin antibody treatment. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 29: 1597-607. PMID 24470143 DOI: 10.1002/Jbmr.2188 |
0.673 |
|
| 2013 |
Virk MS, Alaee F, Tang H, Ominsky MS, Ke HZ, Lieberman JR. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. The Journal of Bone and Joint Surgery. American Volume. 95: 694-701. PMID 23595067 DOI: 10.2106/JBJS.L.00285 |
0.481 |
|
| 2013 |
Hamann C, Rauner M, Höhna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Günther KP, Stolina M, Han CY, Asuncion FJ, Ominsky MS, Hofbauer LC. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 627-38. PMID 23109114 DOI: 10.1002/jbmr.1803 |
0.551 |
|
| 2013 |
Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 73-80. PMID 22836659 DOI: 10.1002/Jbmr.1717 |
0.71 |
|
| 2013 |
Ominsky M, Li X, Warmington K, Niu Q, Asuncion F, Dwyer D, Grisanti M, Han C, Kostenuik P, Stolina M, Ke H. THU0397 Increased Bone Mass and Bone Strength by Sclerostin Antibody (Scl-Ab) is Maintained by a RANKL Inhibitor in OVX Rats with Established Osteopenia Annals of the Rheumatic Diseases. 72: A299.3-A300. DOI: 10.1136/Annrheumdis-2013-Eular.925 |
0.545 |
|
| 2013 |
Ominsky MS, Samadfam R, Jolette J, Smith SY, Ke HZ, Boyce R. THU0396 Six Months of Sclerostin Antibody Treatment in Cynomolgus Monkeys: Sustained Improvements in Vertebral Microarchitecture and Bone Strength Following a Temporal Increase in Cancellous Bone Formation Annals of the Rheumatic Diseases. 72: A299.2-A299. DOI: 10.1136/annrheumdis-2013-eular.924 |
0.675 |
|
| 2013 |
Ominsky M, Niu Q, Ke H. OP0042 Increased modeling-based bone formation and decreased bone resorption on endocortical surfaces in male cynomolgus monkeys treated with sclerostin antibody Annals of the Rheumatic Diseases. 71: 67.1-67. DOI: 10.1136/annrheumdis-2012-eular.1725 |
0.661 |
|
| 2012 |
Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocrine Reviews. 33: 747-83. PMID 22723594 DOI: 10.1210/Er.2011-1060 |
0.717 |
|
| 2012 |
Shahnazari M, Dwyer D, Chu V, Asuncion F, Stolina M, Ominsky M, Kostenuik P, Halloran B. Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone. 50: 628-37. PMID 22154841 DOI: 10.1016/j.bone.2011.11.010 |
0.62 |
|
| 2012 |
Hamann⁎ C, Höhna Y, Rauner M, Mettelsiefen J, Göttsch C, Bernhardt R, Günther K, Ominsky M, Hofbauer L. Sclerostin inhibition increases bone mass and bone defect regeneration in rats with type 2 diabetes mellitus Bone. 50: S71-S72. DOI: 10.1016/j.bone.2012.02.202 |
0.541 |
|
| 2012 |
Achiou Z, Benaitreau⁎ D, Pallu S, Dolléans E, Lespessailles E, Ominsky M, Benhamou C. Sclerostin antibody treatment enhances BMD and trabecular bone microarchitecture in male rats treated with glucocorticoids Bone. 50: S57-S58. DOI: 10.1016/j.bone.2012.02.157 |
0.573 |
|
| 2012 |
Chappard D, Ammann P, Ominsky M, Behets C, Devogelaer⁎ J, Manicourt D. Sclerostin neutralizing monoclonal antibody decreases significantly the number of pelvic fractures and improves dramatically the size and interconnectivity of lumbar trabecular bone in oim/oim mice Bone. 50: S35. DOI: 10.1016/j.bone.2012.02.089 |
0.559 |
|
| 2012 |
Ominsky⁎ M, Niu Q, Ke H. Sclerostin antibody increased modeling-based bone formation and decreased bone resorption on endocortical surfaces in male cynomolgus monkeys Bone. 50: S34. DOI: 10.1016/j.bone.2012.02.087 |
0.654 |
|
| 2011 |
Li C, Ominsky MS, Tan HL, Barrero M, Niu QT, Asuncion FJ, Lee E, Liu M, Simonet WS, Paszty C, Ke HZ. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone. 49: 1178-85. PMID 21890008 DOI: 10.1016/j.bone.2011.08.012 |
0.56 |
|
| 2011 |
Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, Han CY, Yu L, Lee J, Lee E, Barrero M, Kurimoto P, Niu QT, Geng Z, Winters A, ... ... Ominsky MS, et al. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 26: 2610-21. PMID 21773994 DOI: 10.1002/Jbmr.472 |
0.655 |
|
| 2011 |
Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 152: 3312-22. PMID 21733832 DOI: 10.1210/En.2011-0252 |
0.659 |
|
| 2011 |
Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 26: 1012-21. PMID 21542004 DOI: 10.1002/Jbmr.307 |
0.657 |
|
| 2011 |
Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 49: 162-73. PMID 21497676 DOI: 10.1016/j.bone.2011.04.001 |
0.682 |
|
| 2011 |
Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone. 49: 151-61. PMID 21457806 DOI: 10.1016/j.bone.2011.03.769 |
0.667 |
|
| 2011 |
Campbell GM, Ominsky MS, Boyd SK. Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of the Usa. 22: 931-42. PMID 20480144 DOI: 10.1007/s00198-010-1283-5 |
0.567 |
|
| 2010 |
Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F, Li X, Ominsky M, Richards W, Schett G, Zwerina J. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Annals of the Rheumatic Diseases. 69: 2152-9. PMID 20858621 DOI: 10.1136/ard.2010.132852 |
0.604 |
|
| 2010 |
Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 25: 2647-56. PMID 20641040 DOI: 10.1002/Jbmr.182 |
0.669 |
|
| 2010 |
Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. The Journal of Biological Chemistry. 285: 28164-73. PMID 20558734 DOI: 10.1074/jbc.M110.101964 |
0.678 |
|
| 2010 |
Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 25: 2256-65. PMID 20533525 DOI: 10.1002/jbmr.149 |
0.668 |
|
| 2010 |
Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 25: 948-59. PMID 20200929 DOI: 10.1002/Jbmr.14 |
0.708 |
|
| 2009 |
Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone. 45: 669-76. PMID 19539794 DOI: 10.1016/J.Bone.2009.06.011 |
0.64 |
|
| 2009 |
Ohishi M, Chiusaroli R, Ominsky M, Asuncion F, Thomas C, Khatri R, Kostenuik P, Schipani E. Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor. The American Journal of Pathology. 174: 2160-71. PMID 19389927 DOI: 10.2353/ajpath.2009.081026 |
0.658 |
|
| 2009 |
Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 24: 1234-46. PMID 19257823 DOI: 10.1359/Jbmr.090215 |
0.606 |
|
| 2009 |
Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 24: 578-88. PMID 19049336 DOI: 10.1359/Jbmr.081206 |
0.702 |
|
| 2009 |
Gerstenfeld LC, Sacks DJ, Pelis M, Mason ZD, Graves DT, Barrero M, Ominsky MS, Kostenuik PJ, Morgan EF, Einhorn TA. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 24: 196-208. PMID 19016594 DOI: 10.1359/Jbmr.081113 |
0.452 |
|
| 2009 |
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, ... ... Ominsky MS, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 24: 182-95. PMID 19016581 DOI: 10.1359/Jbmr.081112 |
0.621 |
|
| 2009 |
Ominsky M, Smith S, Jolette J, Vlasseros F, Samadfam R, Kostenuik P. Further reductions in bone turnover after transition from alendronate to denosumab in ovariectomized cynomolgus monkeys resulted in maintained or improved cortical and trabecular bone mass and bone strength Bone. 44: S438-S439. DOI: 10.1016/j.bone.2009.03.395 |
0.667 |
|
| 2008 |
Lloyd SA, Yuan YY, Kostenuik PJ, Ominsky MS, Lau AG, Morony S, Stolina M, Asuncion FJ, Bateman TA. Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcified Tissue International. 82: 361-72. PMID 18465074 DOI: 10.1007/S00223-008-9133-6 |
0.681 |
|
| 2008 |
Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 23: 672-82. PMID 18433301 DOI: 10.1359/Jbmr.080109 |
0.653 |
|
| 2008 |
Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 23: 860-9. PMID 18269310 DOI: 10.1359/Jbmr.080216 |
0.637 |
|
| 2008 |
Yuan YY, Kostenuik PJ, Ominsky MS, Morony S, Adamu S, Simionescu DT, Basalyga DM, Asuncion FJ, Bateman TA. Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of the Usa. 19: 625-35. PMID 18038244 DOI: 10.1007/S00198-007-0509-7 |
0.649 |
|
| 2007 |
Stolina M, Dwyer D, Ominsky MS, Corbin T, Van G, Bolon B, Sarosi I, McCabe J, Zack DJ, Kostenuik P. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. Journal of Immunology (Baltimore, Md. : 1950). 179: 7497-505. PMID 18025194 |
0.406 |
|
| 2007 |
Ominsky MS, Kostenuik PJ, Cranmer P, Smith SY, Atkinson JE. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of the Usa. 18: 1073-82. PMID 17384898 DOI: 10.1007/s00198-007-0363-7 |
0.585 |
|
| 2007 |
Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. Nature Medicine. 13: 156-63. PMID 17237793 DOI: 10.1038/nm1538 |
0.478 |
|
| 2006 |
Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, ... ... Ominsky MS, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 39: 754-66. PMID 16730481 DOI: 10.1016/J.Bone.2006.03.017 |
0.602 |
|
| 1999 |
Zysset PK, Ominsky MS, Goldstein SA. A Novel 3D Microstructural Model for Trabecular Bone: II. The Relationship Between Fabric and the Yield Surface. Computer Methods in Biomechanics and Biomedical Engineering. 2: 1-11. PMID 11264814 DOI: 10.1080/10255849908907974 |
0.543 |
|
| 1998 |
Zysset PK, Ominsky MS, Goldstein SA. A Novel 3D Microstructural Model for Trabecular Bone: I. The Relationship between Fabric and Elasticity. Computer Methods in Biomechanics and Biomedical Engineering. 1: 321-331. PMID 11264812 DOI: 10.1080/01495739808936710 |
0.651 |
|
| 1997 |
Ominsky MS, Zysset PK, Goldstein SA. Elastic properties of 3D cells for trabecular bone: Digital vs. structural finite element models American Society of Mechanical Engineers, Bioengineering Division (Publication) Bed. 36: 7-8. |
0.445 |
|
| Show low-probability matches. |